Ahmed Umer Sohaib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed Umer Sohaib has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Asmat Ullah
College of Pharmaceutical Sciences Zhejiang University of Technology Hangzhou China
1 shared publication - Hebatallah Ahmed Mohamed Moustafa
Badr University In Cairo
1 shared publication Iqra Saleem
Department of Pharmaceutical Sciences,Swedish College of Pharmacy and Allied Health Sciences, Rahim Yar Khan, Pakistan
1 shared publication
Latest Publications
- Top Cited Papers
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (1) , 17-26
Targeting of YKL-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding
Background: Individualization of the therapeutic plan for cancer patients is the essence of modern clinical practice. Standard cancer diagnostic and prognostic factors are invasive, and their value for the stratification of cancer patients with a higher risk of local or distant recurrence is limited. YKL-40 is a protumor glycoprotein linked to the immunosuppressive tumor in a microenvironment and an important biomarker of cell activation, proliferation, and migration. Objective: The objective is to update the review, and molecular and clinical research should investigate novel modalities of targeting this glycoprotein for cancer treatment. Methods: Relevant studies published in the English language were identified by searching PubMed, Google Scholar, and MEDLINE from January 2000 to December 2023. Published studies that specifically elicited the role of YKL-40 as a biomarker in different types of tumors were included. Results: YKL-40 cancer prognostic effect was reported in various cancer types. Conclusion: Since antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 26 (1) , 17-26
Top Cited PapersTargeting of YKL-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding
Background: Individualization of the therapeutic plan for cancer patients is the essence of modern clinical practice. Standard cancer diagnostic and prognostic factors are invasive, and their value for the stratification of cancer patients with a higher risk of local or distant recurrence is limited. YKL-40 is a protumor glycoprotein linked to the immunosuppressive tumor in a microenvironment and an important biomarker of cell activation, proliferation, and migration. Objective: The objective is to update the review, and molecular and clinical research should investigate novel modalities of targeting this glycoprotein for cancer treatment. Methods: Relevant studies published in the English language were identified by searching PubMed, Google Scholar, and MEDLINE from January 2000 to December 2023. Published studies that specifically elicited the role of YKL-40 as a biomarker in different types of tumors were included. Results: YKL-40 cancer prognostic effect was reported in various cancer types. Conclusion: Since antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.